Back to Journals » International Journal of Nanomedicine » Volume 16

Au Catalyzing Control Release NO in vivo and Tumor Growth-Inhibiting Effect in Chemo-Photothermal Combination Therapy

Authors Zhang Y, Zhou T, Li J, Xu N, Cai M, Zhang H, Zhao Q, Wang S

Received 17 July 2020

Accepted for publication 27 February 2021

Published 29 March 2021 Volume 2021:16 Pages 2501—2513


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Linlin Sun

Ying Zhang,1 Tianfu Zhou,1 Jian Li,1 Nuo Xu,1 Mingze Cai,1 Hong Zhang,2 Qinfu Zhao,3 Siling Wang3

1Key Laboratory of TargetDrug Design and Research, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, People’s Republic of China; 2Van ’T Hoff Institute for Molecular Sciences, University of Amsterdam, Amsterdam, 1098 XH, the Netherlands; 3Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016, People’s Republic of China

Correspondence: Qinfu Zhao; Siling Wang Tel/Fax +86 24 43520555
Email [email protected]; [email protected]

Introduction: Aim to obtain a NO donor that can control released NO in vivo with the high efficacy of tumor suppression and targeting, a nanoplatform consisting of FA-Fe3O4@mSiO2-Au/DOX was constructed.
Methods: In vitro, the nanoplatform catalyzed NO’s release with the maximum value of 4.91 μM within 60 min at 43°C pH=5.0, which was increased by 1.14 times when the temperature was 37°C. In vivo, 11.7 μg Au in the tumor tissue was found to catalyze S-nitrosoglutathione continuously, and 54 μM NO was checked out in the urine.
Results and Discussion: The high concentration of NO was found to increase the apoptotic rate and to reduce tumor proliferation. In the chemo-photothermal combination therapy, the tumor inhibition rate was increased up to 94.3%, and Au’s contribution from catalyzing NO release NO was 8.17%.

Keywords: thermotherapy, chemotherapy, NO control release, magnetic mesoporous silica nanocomposites

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]